Pfizer Document Reveals Serious Observed Adverse Events

When you read the following side effects observed and not reported, what goes through your mind. Why have they concealed and continued to push a toxic substance masquerading as a vaccine.

The report for the evaluation of post authorisation vaccine use has been hidden from public scrutiny. On a review of the various topics made available in the evaluation, note the following:

5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports
Table 5. Important Potential Risk

Important Potential RiskPost Authorization Cases Evaluation (cumulative to 28 Feb 2021)
Total Number of Cases in the Reporting Period (N=42086)
Vaccine Associated Enhanced Disease (VAED),
including Vaccine Associated Enhanced
Respiratory Disease (VAERD)
No post-authorized AE reports have been identified as cases of VAED/VAERD, therefore, there is no observed data at this time. An expected rate of VAED is difficult to establish so a meaningful observed/expected analysis cannot be conducted at this point based on available data. The feasibility of
conducting such an analysis will be re-evaluated on an ongoing basis as data on the virus grows and the vaccine safety data continues to accrue.

The search criteria utilised to identify potential cases of VAED for this report includes PTs indicating a lack of effect of the vaccine and PTs potentially indicative of severe or atypical COVID-19a .
Since the first temporary authorization for emergency supply under Regulation 174 in the UK (01 December 2020) and through 28 February 2021, 138 cases [0.33% of the total PM dataset], reporting 317 potentially relevant events were retrieved:

Country of incidence: UK (71), US (25), Germany (14), France, Italy, Mexico, Spain, (4 each), Denmark (3); the remaining 9 cases originated from 9 different countries;

Cases Seriousness: 138;
Seriousness criteria for the total 138 cases: Medically significant (71, of which 8 also serious for disability), Hospitalization required (non-fatal/non-life threatening) (16, of which 1 also serious for disability), Life threatening (13, of which 7 were also serious for hospitalization), Death (38).

Gender: Females (73), Males (57), Unknown (8);
Age (n=132) ranged from 21 to 100 years (mean = 57.2 years, median = 59.5);
Case outcome: fatal (38), resolved/resolving (26), not resolved (65), resolved with sequelae (1), unknown (8);
Of the 317 relevant events, the most frequently reported PTs (≥2%) were: Drug ineffective (135), Dyspnoea (53), Diarrhoea (30), COVID-19 pneumonia (23), Vomiting (20), Respiratory failure (8), and Seizure (7).

Conclusion: VAED may present as severe or unusual clinical manifestations of COVID-19. Overall, there were 37 subjects with suspected COVID-19 and 101 subjects with confirmed COVID-19 following one or both doses of the vaccine; 75 of the 101 cases were severe, resulting in hospitalisation, disability, life-threatening consequences or death. None of the 75 cases could be definitively considered as VAED/VAERD.

In this review of subjects with COVID-19 following vaccination, based on the current evidence, VAED/VAERD remains a theoretical risk for the vaccine. Surveillance will continue.
Download Report
Choose your Reaction!
Leave a Comment

Your email address will not be published.